
Your Feed
Phase 1b-2 Dose Escalation Study Sonrotoclax + Dexamethasone | Binod Dhakal, MD | EHA 2024
CARTITUDE-4 Subgroup Analysis of Functional High-Risk Patients | Luciano Costa, MD | EHA 2024
Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 Trial | Luciano Costa, MD | EHA 2024
MAJESTIC-1 Study - A Subgroup Analysis of High-risk Patients | Luciano Costa, MD | EHA2024
ASCO/EHA Myeloma Updates 2024 | Claudio Cerchione, MD | EHA 2024
The Role of Combination FDG PET Plus Whole Body MRI for Staging | Claudio Cerchione, MD | EHA 2024
Epcoritamab's Impact on Treating Relapsed Follicular Lymphoma | Umberto Vitolo, MD | EHA 2024
Bispecific Antibodies and Precision Medicine Insights on Myeloma Prognosis | Ola Landgren, MD | EHA 2024
Administering Outpatient CAR T-cell Therapy in Non-Hodgkin Lymphoma | Radhika Bansal, MD | EHA 2024
Real World Outcomes of RRMM Using Kyprolis | Sharlene Dong, MD, MS | EHA 2024










